Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;31(2):310-317.
doi: 10.1038/leu.2016.225. Epub 2016 Sep 2.

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

A K Burnett  1 , N H Russell  2 , R K Hills  3 , J Kell  4 , O J Nielsen  5 , M Dennis  6 , P Cahalin  7 , C Pocock  8 , S Ali  9 , S Burns  3 , S Freeman  10 , D Milligan  11 , R E Clark  12
Affiliations

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia

A K Burnett et al. Leukemia. 2017 Feb.

Abstract

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and normal serum creatinine were randomised to two courses of induction chemotherapy with either daunorubicin/ara-C (DA) or daunorubicin/clofarabine (DClo). Patients were also included in additional randomisations; ± one dose of gemtuzumab ozogamicin in course 1; 2v3 courses and ± azacitidine maintenance. The primary end point was overall survival. The overall response rate was 69% (complete remission (CR) 60%; CRi 9%), with no difference between DA (71%) and DClo (66%). There was no difference in 30-/60-day mortality or toxicity: significantly more supportive care was required in the DA arm even though platelet and neutrophil recovery was significantly slower with DClo. There were no differences in cumulative incidence of relapse (74% vs 68%; hazard ratio (HR) 0.93 (0.77-1.14), P=0.5); survival from relapse (7% vs 9%; HR 0.96 (0.77-1.19), P=0.7); relapse-free (31% vs 32%; HR 1.02 (0.83-1.24), P=0.9) or overall survival (23% vs 22%; HR 1.08 (0.93-1.26), P=0.3). Clofarabine 20 mg/m2 given for 5 days with daunorubicin is not superior to ara-C+daunorubicin as induction for older patients with AML/high-risk MDS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial design of AML16 (acute myeloid leukemia; intensive arm) from 2006 to 2009. C, course; CR, complete remission; PR, partial remission; Rx, treatment.
Figure 2
Figure 2
CONSORT diagram.
Figure 3
Figure 3
Outcomes. (a) Cumulative incidence of relapse; (b) survival post relapse; (c) relapse-free survival; and (d) survival from CR.
Figure 4
Figure 4
Overall survival: (a) survival by arm and (b) histogram of causes of death.
See this image and copyright information in PMC

References

    1. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematol Am Soc Hematol Educ Program 2012; 2012: 1–6. - PubMed
    1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487–494. - PubMed
    1. Lowenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscheret L et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ yrs. with acute myeloid leukemia. A randomized phase III study (AML-7) of the EORTC Leukemia Group. J Clin Oncol 1989; 7: 1268–1274. - PubMed
    1. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61–69. - PubMed
    1. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106: 1090–1098. - PubMed

MeSH terms